THE ROLE OF SURVIVIN AND RAF-1 KINASE AGAINST ENHANCEMENT OF PANCREATIC BETA-CELL APOPTOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS by Decroli, Eva et al.
Vol 11, Issue 11, 2018
Online - 2455-3891 
Print - 0974-2441
THE ROLE OF SURVIVIN AND RAF-1 KINASE AGAINST ENHANCEMENT OF PANCREATIC 
BETA-CELL APOPTOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
EVA DECROLI1*, ASMAN MANAF1, SYAFRIL SYAHBUDDIN1, SARWONO WASPADJI2, DWISARI DILLASAMOLA3
1Endocrinology and Metabolic Subdivision, Division of Internal Medicine, Dr. M. Djamil General Hospital/Medical Faculty, Andalas 
University, Padang, Indonesia. 2Endocrinology and Metabolic Subdivision, Division of Internal Medicine, Medical Faculty, Indonesia 
University, Jakarta, Indonesia. 3Department of Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine Universitas 
Indonesia, Jakarta, Indonesia. Email: evadecroli@med.unand.ac.id
Received: 04 June 2018, Revised and Accepted: 20 July 2018
ABSTRACT
Objective: This study aimed to reveal differences in levels of survivin and Raf-1 kinase in prediabetes, controlled Type 2 diabetes mellitus (T2DM), 
uncontrolled T2DM, and their relationship with hemoglobin A1c (HbA1c) levels and serum triglyceride levels.
Methods: This study was an observational study with a cross-sectional design. The study involved 60 people with T2DM who visited the endocrine 
and metabolic clinic and 30 prediabetes patients. The variables were survivin levels and Raf-1 kinase enzymes that examined using enzyme-linked 
immunosorbent assay techniques. HbA1c values are measured by high-performance liquid chromatography and triglyceride levels measured by 
enzymatic method.
Results: Average levels of Raf-1 kinase were significantly higher in the prediabetes group, controlled T2DM, and uncontrolled T2DM (11.6±1.4 pg mL, 




Conclusion: Survivin and Raf-1 kinase levels are lower in uncontrolled T2DM. This explained the role of survivin and Raf-1 kinase against enhancement 
of pancreatic beta-cell apoptosis in patients with T2DM.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a metabolic endocrine disorder 
that started with prediabetes. T2DM is a disease that is being a major 
threat to human health in the 21st century. Based on estimation made 
by the World Health Organization that, in 2000, the number of people 
with diabetes over the age of 20 years is up to 150 million people and 
over a period of 25 years later, in 2025, this number will increase to 300 
million people [1-5].
Pancreatic beta cells defect and insulin resistance factor play a role in 
the pathogenesis of T2DM insulin resistance factor. Pancreatic beta cells 
function decreased by glucotoxicity because of the imbalance between 
proliferation and apoptosis of pancreatic beta cells. Beside lipotoxicity 
and glucotoxicity which affect pancreatic beta cells, it is noted also that 
in molecular basis there is some specific protein named survivin and 
the Raf-1 kinase that contribute the life of the beta cell. Survivin has the 
power to preserve beta cells from apoptosis whereas the Raf-1 kinase 
has the power to proliferate pancreatic beta cells [2,6-8].
Survivin is a protein that regulates the replication and survival of 
pancreatic beta cells, expressed during embryogenesis endocrine 
cells that undergo proliferation. The main function of the protein is to 
inhibit apoptosis and also regulate cell division. This protein contains 
a baculovirus inhibitor of apoptosis protein (IAP) repeat domain (BIR 
domain) that makes survivin is grouped into the IAP [8].
Raf 1 kinase is part of serine protein group/threonine kinase consisting 
of A-Raf, B-Raf, and C-Raf. Raf-1 kinase is also known as C-Raf that plays 
a role in signal transduction RAS-RAF-MEK-ERK. Activation of Raf-1 
kinase signal transduction pathways lead mitogen-activated protein 
kinase (MAPK), and MAP3K become more active. These protein work in 
the downstream area of Ras proteins [7].
Raf-1 kinase has a major role to proliferate in some cells including 
pancreatic beta cells. When raf-1 kinase was blocked by Raf-1 inhibitor, 
it would increase cell death due to proliferation inhibition in pancreatic 
beta cells. Raf-1 kinase specifically works to control cell proliferation to 
maintain the quantity of pancreatic beta cells [7].
On the progression of prediabetes and T2DM, pancreatic beta cells 
condition was unknown, whereas pancreatic beta cells play an 
important role in the etiopathogenesis of prediabetes and T2DM. 
Therefore, the study of survivin and Raf-1 kinase against enhancement 
of pancreatic beta cells apoptosis in patients with T2DM is important to 
understand the pathophysiology of diabetes.
METHODS
This study is an observational study with a cross-sectional design. This 
study involved 60 patients who visited the clinic of T2DM metabolic 
Endocrinology Department of Dr. M. Djamil Hospital Padang and 
30 people with prediabetes are obtained from family or children of 
persons with T2DM. Patients were divided into groups of uncontrolled 
T2DM, controlled T2DM, and prediabetes. Patients’ blood was collected 
for laboratory examination. Some of the analyzed variables were levels 
of survivin and Raf-1 kinase levels that represent the pancreatic beta-
cell defects. These two variables were associated with blood sugar 
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control reflected by hemoglobin A1c (HbA1c) and triglyceride levels. 
All patients have provided signed consent. Ethical approval was granted 
by Medical Faculty University of Andalas Research Ethics Committee.
Examination methods
Survivin levels and Raf-1 kinase enzymes were examined using 
enzyme-linked immunosorbent assay techniques. HbA1c was checked 
using the method of high-performance liquid chromatography, whereas 
triglyceride was examined using enzymatic methods.
Statistical analysis
Categorical scale data were written in frequencies and percentages 
while interval data or ratio scale was written in mean ± standard 
deviation. Difference in the two averages was normally tested using t 




Observational studies had been conducted with a cross-sectional 
design in patients with T2DM and prediabetes patients. In Table 1, it 
could be seen that the subjects were as many as 90 subjects, consisted 
of 30 prediabetes subjects, and 60 T2DM subjects. On the subjects 
of  prediabetes,  fasting  blood  glucose was  <126 mg/dL,  and  2-h  oral 
glucose tolerance blood glucose was <200 mg/dL. In the diabetic group 
either controlled or uncontrolled, fasting blood glucose levels were 
>126 mg/dL, and 2-h oral glucose tolerance blood glucose was over 
200 mg/dL. Research’s subjects characteristics can be seen in Table 1.
Differences in levels of survivin and Raf-1 kinase between 
prediabetes, controlled diabetes, and uncontrolled diabetes 
groups
In this study, both survivin and Raf-1 kinase had differences in groups 
of prediabetes, controlled T2DM, and uncontrolled T2DM. Survivin 
was significantly higher in the prediabetes group compared with the 
controlled T2DM group. Survivin was also higher in the controlled 
T2DM than uncontrolled T2DM. The same thing was found in Raf-1 
kinase (Figs. 1 and 2).
Correlation between survivin and Raf-1 kinase with HbA1c
To assess the relationship of HbA1c with survivin protein and Raf-1 
kinase, we tested two variables with the Spearman correlation test. In the 
correlation test, we found a negative correlation between survivin with 
HbA1c (p<0.05) and Raf-1 kinase with HbA1c (p=0.250) (Figs. 3    and 4).
The correlation between serum triglycerides with survivin and 
Raf-1 kinase
It is only to describe whether blood lipid levels affect survivin levels and 
Raf-1 kinase. In this study, a negative correlation was found between 
serum triglycerides with survivin, but not with the Raf-1 kinase 
(Table 2).
DISCUSSIONS
Results of statistical tests in this study find a significant difference 
between the levels of survivin in the prediabetes group and the controlled 
T2DM group with an uncontrolled T2DM group (p<0.05). This suggests 
differences in the level of destruction of pancreatic beta cells in these 
three groups. Wang defined a mechanism of survivin regulation by EGF 
through the Raf-1/MEK/ERK pathway in pancreatic beta cells, through 
prolongation of survivin protein half-life and inhibition of the ubiquitin-
mediated proteasomal degradation pathway. In prediabetes, survivin 
levels are higher than uncontrolled T2DM. The lower levels of survivin 
in uncontrolled T2DM can impair pancreatic beta cells ability to defend 
from damage because of glucotoxicity. The high levels of survivin in 
prediabetes are expected to prevent the pancreatic beta cells damage. 
Prediabetes is a condition that can reverse to normal, still, survive as 
prediabetes or progress to T2DM. In people with prediabetes, it is found 
that beta-cell dysfunction is still reversible [9,10].
Fig. 1: Mean levels of survivin in the prediabetes, controlled, and 
uncontrolled Type 2 diabetes mellitus group
Fig. 2: Average levels of Raf-1 kinase in the prediabetes, 
controlled, and uncontrolled Type 2 diabetes mellitus group
Table 1: Characteristics of the sample and the mean levels of survivin and Raf-1 kinase in the prediabetes, controlled, and uncontrolled 
T2DM group
Characteristics Prediabetes (n=30) Controlled T2DM (n=30) Uncontrolled T2DM (n=30)
Age (years) 52.9±10.1 58.2±10.7 55.3±8.1
FBG (mg/dL) 105.7±8.5 140.8±15.9 211.1±15.6
BG-2hrOGTT (mg/dL) 175.9±15.8 279.4±41.1 282.9±30.8
HbA1c (%) - 6.4±0.3 9.2±2.1
Triglyceride (mg/dL) - 131.3±56.5 156.7±99.9
Raf (pg/mL) 11.6±1.4 9.9±1.1 9.1±1.5
Survivin (pg/mL) 5.4±0.4 5.0±0.2 4.7±0.1
HbA1c: Hemoglobin A1c, T2DM: Type 2 diabetes mellitus
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At T2DM, chronic hyperglycemia has occurred that is very crucial for 
pancreatic beta-cell function deterioration, which can lead to beta-
cell failure. Beta-cell failure is such a worst result of glycemic control 
in patients with T2DM [11]. Defective pancreatic beta cells are then 
reflected by the worsening effort in regenerating cells, as reflected in 
low levels of survivin and Raf-1 kinase [12,13].
This study finds a significant inverse relationship between survivin 
levels with HbA1c levels in the group of patients with T2DM. In 
patients with T2DM with HbA1c levels >7% which means bad glycemic 
control, long glucotoxicity process that can damage pancreatic beta 
cells by increasing apoptosis, which is characterized by low levels 
of survivin. Wu et al. indicated that survivin is essential for beta-cell 
mass expansion and appeared to exhibit a preferential requirement for 
proliferation of preexisting beta cells. The lower levels of survivin in this 
study may cause by pancreatic beta cells mitochondria damage because 
of glucotoxicity. It shows that in patients with uncontrolled T2DM, 
destruction of pancreatic beta cells will be increasing, characterized 
by low levels of survivin. In the management of diabetes, HbA1C levels 
can be lowered, but the impact of previous glucotoxicity process is 
irreversible, so whenever HbA1c levels are reduced, survivin levels will 
not increase [13,14].
Results of statistical tests in this study find a significant difference 
between the levels of Raf-1 kinase in the prediabetes group and the 
controlled  T2DM  group  with  uncontrolled  T2DM  group  (p<0.05). 
In this study, there is no significant correlation between HbA1c 
with Raf-1 kinase in T2DM group, mean that the increase in HbA1C 
levels is not necessarily degrading Raf-1 kinase. It is suspected that 
chronic hyperglycemia is a factor that could destroy pancreatic beta 
cells, that does not show a direct effect on Raf-1 kinase but work 
in conjunction with other PKs such as PI3 kinase and survivin PKC. 
In Raf-1 kinase against HbA1C correlation, it is shown that chronic 
hyperglycemia impairs survivin earlier than Raf-1 kinase. Beith found 
that overexpression of Raf-1 was sufficient to increase proliferation 
in the absence of insulin, whereas a dominant-negative Raf-1 reduced 
proliferation in the presence of insulin. In this study, the lower levels of 
Raf-1 kinase in uncontrolled T2DM can impair the pancreatic beta cells 
ability to proliferate [7,12,13,15].
Statistically, in this study, there is a significant negative correlation 
with the weak correlation between serum triglyceride levels with 
serum survivin levels at the T2DM group. Statistical test with statistical 
methods of linear regression shows that high triglyceride levels in 
patients with T2DM relate with the low levels of survivin. This assumes 
that survivin is more easily influenced by triglycerides, but it still does 
not find a certain explanation. Ju et al. found that survivin attenuated 
DNA damage-related stress responses suggesting that survivin 
may facilitate adipocyte maintenance in response to inflammatory 
stimuli [8,12,16]. Fatty acid is a contributing factor in the growth and 
survival of mature pancreatic beta cells with the effect of reducing 
proliferation and lowering survival [17,18].
CONCLUSION
Survivin and Raf-1 kinase levels are lower in uncontrolled T2DM. This 
explained the role of survivin and Raf-1 kinase against enhancement of 
pancreatic beta-cell apoptosis in patients with T2DM.
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